The Shanghai-based provider of global drug research, development and manufacturing services will sell the shares at HK$104.27 apiece, a 6.9% discount to Wednesday’s closing price, it said in a statement. The stock fell as much as 6.9% in Hong Kong on Thursday.
The share placement could bring “longer-term upside to its earnings outlook, outweighing any near-term concerns of dilution,” according to Bloomberg Intelligence analyst
The company ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.